[Translation] A single-center, randomized, open-label, fasting and postprandial single-dose, two-formulation, two-sequence, four-period, fully repeated crossover bioequivalence study of rosuvastatin ezetimibe tablets (I) in healthy adult Chinese subjects
考察空腹/餐后单次口服受试制剂瑞舒伐他汀依折麦布片(I)【规格:每片含依折麦布10mg与瑞舒伐他汀钙10mg,湖南千金湘江药业股份有限公司持有】与参比制剂依折麦布瑞舒伐他汀钙片【商品名:Zenon®,每片含依折麦布10mg与瑞舒伐他汀钙10mg,Sanofi-Aventis Deutschland GmbH持证,Sanofi Ilac Sanayi ve Ticaret Anonim Sirketi生产】,在中国成年健康人体的相对生物利用度,分析两种制剂的药代动力学参数,评价两制剂的生物等效性。
[Translation] The relative bioavailability of the test preparation rosuvastatin ezetimibe tablets (I) [Specification: each tablet contains 10 mg ezetimibe and 10 mg rosuvastatin calcium, owned by Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd.] and the reference preparation ezetimibe rosuvastatin calcium tablets [trade name: Zenon®, each tablet contains 10 mg ezetimibe and 10 mg rosuvastatin calcium, licensed by Sanofi-Aventis Deutschland GmbH, produced by Sanofi Ilac Sanayi ve Ticaret Anonim Sirketi] after a single oral fasting/postprandial dose in healthy Chinese adults was investigated, the pharmacokinetic parameters of the two preparations were analyzed, and the bioequivalence of the two preparations was evaluated.